Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)
NCT04923802 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 13
Last updated 2024-03-08
Summary
This multicenter prospective observational and exploratory study aims to develop and validate a novel multi-omics-based computational method for neoantigen prediction in non-small cell lung cancer (NSCLC), and discover biomarkers for evaluation of PD-1/PD-L1 inhibitor's efficacy in patients of advanced NSCLC.
Conditions
- Non-small Cell Lung Cancer
- Neoantigen
- Next-generation Sequencing
- Biomarker
Sponsors & Collaborators
-
Xinqiao Hospital of Chongqing
collaborator OTHER -
Shanghai Pulmonary Hospital, Shanghai, China
collaborator OTHER -
Shanghai Chest Hospital
collaborator OTHER -
Wuhan University
collaborator OTHER -
Renmin Hospital of Wuhan University
collaborator OTHER -
Tongji Hospital
collaborator OTHER -
Southwest Hospital, China
collaborator OTHER -
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
collaborator OTHER -
People's Hospital of Chongqing
collaborator OTHER -
Sichuan Cancer Hospital and Research Institute
collaborator OTHER -
The Second Affiliated Hospital of Kunming Medical University
collaborator OTHER -
First Affiliated Hospital of Wenzhou Medical University
collaborator OTHER -
The Affiliated Hospital Of Southwest Medical University
collaborator OTHER -
Guizhou Provincial People's Hospital
collaborator OTHER -
The First Affiliated Hospital of Zhengzhou University
collaborator OTHER -
Shaanxi Provincial Cancer Hospital
collaborator OTHER -
First Hospital of China Medical University
collaborator OTHER -
Fujian Provincial Hospital
collaborator OTHER -
Peking University Shenzhen Hospital
collaborator OTHER -
Affiliated Cancer Hospital of Shantou University Medical College
collaborator OTHER -
The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
collaborator OTHER -
GeneCast Biotechnology Co., Ltd.
lead INDUSTRY
Principal Investigators
-
Bo Zhu · Xinqiao Hospital of Chongqing
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-24
- Primary Completion
- 2021-12-31
- Completion
- 2021-12-31
Countries
- China
Study Locations
More Related Trials
-
Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion
NCT04263688 ·Status: UNKNOWN
-
NGS-based Comprehensive Genomic ctDNA Panel in NSCLC With Immunotherapy
NCT04636047 ·Status: UNKNOWN
-
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
NCT06617390 ·Status: COMPLETED
-
Identify Prognostic Biomarkers of Lung Cancer
NCT05010330 ·Status: UNKNOWN
-
Investigation on Predictive Molecular Markers of Efficacy for Front-line Immunochemotherapy in Advanced NSCLC
NCT04858828 ·Status: UNKNOWN
-
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
NCT04984148 ·Status: UNKNOWN
-
Gut Microbiota and Cancer Immunotherapy Response
NCT04682327 ·Status: UNKNOWN
-
Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy
NCT07256002 ·Status: ACTIVE_NOT_RECRUITING
-
Multi-dimensional Signatures for Precisely Predicting the Response and Prognosis of Lung Cancer Patients
NCT04980352 ·Status: UNKNOWN
-
Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC
NCT06613308 ·Status: NOT_YET_RECRUITING
-
Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung Cancer
NCT04553601 ·Status: UNKNOWN ·Phase: NA
-
Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer
NCT06895941 ·Status: WITHDRAWN
-
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
NCT04076228 ·Status: COMPLETED
-
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
NCT06869239 ·Status: RECRUITING
-
The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer
NCT06287320 ·Status: RECRUITING
-
A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
NCT03373955 ·Status: UNKNOWN
-
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
NCT06699979 ·Status: RECRUITING
-
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
NCT06183762 ·Status: RECRUITING
-
Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
NCT07059923 ·Status: RECRUITING
-
Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor
NCT04932343 ·Status: UNKNOWN
-
Decoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach（Radiogenomics-Lung）
NCT06500312 ·Status: RECRUITING
-
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China
NCT03059641 ·Status: COMPLETED
-
Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer
NCT03317080 ·Status: UNKNOWN
-
Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
NCT07287904 ·Status: NOT_YET_RECRUITING
-
Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC
NCT04405661 ·Status: UNKNOWN